×
About 387 results

ALLMedicine™ Papillary Tumors Center

Research & Reviews  183 results

A clinicopathological reappraisal of intraductal papillary neoplasm of the bile duct (I...
https://doi.org/10.1016/j.hpb.2021.03.004
HPB : the Official Journal of the International Hepato Pa... Onoe S, Ebata T et. al.

Apr 9th, 2021 - Intraductal papillary neoplasm of the bile-duct (IPNB) has recently been further subclassified into "so-called IPNBs" (Type-1) and "narrow-sense papillary cholangiocarcinomas" (Type-2), but their differential diagnosis is challenging. This study a...

PTEN R130Q Papillary Tumor of the Pineal Region (PTPR) with Chromosome 10 Loss Successf...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025816
Current Oncology (Toronto, Ont.); Assi HI, Kakati RT et. al.

Apr 3rd, 2021 - Papillary tumors of the pineal region (PTPR) can be observed among adults with poor prognosis and high recurrence rates. Standards of therapy involve total surgical excision along with radiation therapy, with no promising prospects for primary adj...

Malignant Ciliated Muconodular Papillary Tumors of the Lung: A Case Report.
https://doi.org/10.1177/1066896920988359
International Journal of Surgical Pathology; Wang F, Shen MH et. al.

Feb 19th, 2021 - Ciliated muconodular papillary tumors (CMPTs) are rare peripheral lung lesions, characterized by papillary architecture and ciliated columnar cells admixed with mucous cells and basal cells. Only about 50 cases have been reported to date and is ca...

Papillary tumor of the pineal region in pediatric populations: An additional case and s...
https://doi.org/10.1016/j.clineuro.2020.106404
Clinical Neurology and Neurosurgery; Mathkour M, Hanna J et. al.

Dec 28th, 2020 - Papillary tumors of the pineal region (PTPR) are a rare tumor entity first described in 2003, later codified in the 2007 WHO tumor classification system. PTPRs most commonly occur in the third and fourth decades, with exceedingly rare presentation...

Endoscopic pancreaticobiliary drainage with overlength stents to prevent delayed perfor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701946
World Journal of Gastroenterology; Wu L, Liu F et. al.

Dec 14th, 2020 - Endoscopic papillectomy (EP) is rapidly replacing traditional surgical resection and is a less invasive procedure for the treatment of duodenal papillary tumors in selected patients. With the expansion of indications, concerns regarding EP include...

see more →

Guidelines  1 results

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer

Jan 7th, 2020 - The Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  197 results

A clinicopathological reappraisal of intraductal papillary neoplasm of the bile duct (I...
https://doi.org/10.1016/j.hpb.2021.03.004
HPB : the Official Journal of the International Hepato Pa... Onoe S, Ebata T et. al.

Apr 9th, 2021 - Intraductal papillary neoplasm of the bile-duct (IPNB) has recently been further subclassified into "so-called IPNBs" (Type-1) and "narrow-sense papillary cholangiocarcinomas" (Type-2), but their differential diagnosis is challenging. This study a...

PTEN R130Q Papillary Tumor of the Pineal Region (PTPR) with Chromosome 10 Loss Successf...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025816
Current Oncology (Toronto, Ont.); Assi HI, Kakati RT et. al.

Apr 3rd, 2021 - Papillary tumors of the pineal region (PTPR) can be observed among adults with poor prognosis and high recurrence rates. Standards of therapy involve total surgical excision along with radiation therapy, with no promising prospects for primary adj...

Malignant Ciliated Muconodular Papillary Tumors of the Lung: A Case Report.
https://doi.org/10.1177/1066896920988359
International Journal of Surgical Pathology; Wang F, Shen MH et. al.

Feb 19th, 2021 - Ciliated muconodular papillary tumors (CMPTs) are rare peripheral lung lesions, characterized by papillary architecture and ciliated columnar cells admixed with mucous cells and basal cells. Only about 50 cases have been reported to date and is ca...

Papillary tumor of the pineal region in pediatric populations: An additional case and s...
https://doi.org/10.1016/j.clineuro.2020.106404
Clinical Neurology and Neurosurgery; Mathkour M, Hanna J et. al.

Dec 28th, 2020 - Papillary tumors of the pineal region (PTPR) are a rare tumor entity first described in 2003, later codified in the 2007 WHO tumor classification system. PTPRs most commonly occur in the third and fourth decades, with exceedingly rare presentation...

Endoscopic pancreaticobiliary drainage with overlength stents to prevent delayed perfor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701946
World Journal of Gastroenterology; Wu L, Liu F et. al.

Dec 14th, 2020 - Endoscopic papillectomy (EP) is rapidly replacing traditional surgical resection and is a less invasive procedure for the treatment of duodenal papillary tumors in selected patients. With the expansion of indications, concerns regarding EP include...

see more →

News  5 results

Fast Five Quiz: Urothelial Carcinoma
https://reference.medscape.com/viewarticle/935309_2

Aug 12th, 2020 - Figure 1. Bladder cancer. Illustration of sagittal section of the female pelvis showing cancer in the muscular wall of the bladder. Additional anatomy shown includes the uterus, vagina, and portions of the rectum and small intestine. Low-grade pro...

FDA approves pembrolizumab for BCG-unresponsive NMIBC with CIS
https://www.mdedge.com/hematology-oncology/article/215228/genitourinary-cancer/fda-approves-pembrolizumab-bcg-unresponsive?channel=39313
Laura Nikolaides

Jan 8th, 2020 - The Food and Drug Administration has approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or with.

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer

Jan 7th, 2020 - The Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)...

Expanding the Scope of Cystoscopy: Imaging Agent Illuminates More Lesions
https://www.onclive.com/publications/oncology-live/2011/september-2011/expanding-the-scope-of-cystoscopy-imaging-agent-illuminates-more-lesions

Oct 10th, 2011 - Neal D. Shore, MD Although cystoscopy is a mainstay in diagnosing bladder cancer and monitoring its recurrence, researchers have been seeking to improve upon its ability to detect early evidence of cancer, particularly flat lesions and small papil...

Role of Immunotherapy in Renal Cell Carcinoma
https://www.medscape.com/viewarticle/408449

Abstract and Introduction Renal cell carcinoma develops in over 30,000 individuals annually in the United States, with 12,000 deaths attributed to this tumor on a yearly basis. The etiology of this neoplasm is unknown, but cigarette use appears to...

see more →